The EU-Mercosur trade provisions take effect May 1, bringing phased tariff reductions of up to 16% on medical devices entering Brazil, Argentina, Uruguay, and Paraguay. This edition also covers COFEPRIS's formal MDSAP-NOM 241 GMP equivalence recognition, ANVISA's proposal to make MDSAP mandatory for international device manufacturers, and Ecuador's tightened device storage and distribution certification.
Brazil · Mexico · EU-Mercosur · Ecuador
The EU-Mercosur trade provisions take effect May 1, bringing phased tariff reductions of up to 16% on medical devices entering Brazil, Argentina, Uruguay, and Paraguay. But tariffs are only one piece of a much larger structural shift. This week: COFEPRIS formally recognizes MDSAP as equivalent to Mexico's GMP standard, ANVISA signals mandatory MDSAP for all international manufacturers, and Ecuador tightens device storage and distribution certification — all within 30 days of each other.
ANVISA's 2026-2027 Regulatory Agenda (Ordinance No. 1.484/2025, effective January 1, 2026) includes 14 device-specific topics that will reshape how manufacturers operate in Latin America's largest market. The most consequential: a proposed revision of RDC 687/2022 to make MDSAP certification mandatory for all international medical device manufacturers as the primary GMP pathway — potentially eliminating direct ANVISA foreign inspections altogether.
The agenda also prioritizes revising the SaMD framework (RDC 657/2022) to address cybersecurity, AI-driven software, and lifecycle controls. Brazil currently has over 500 registered software products for diagnostic or therapeutic purposes, including dozens with AI features. Vigilance modernization and full operationalization of the national UDI database (SIUD) round out the device priorities.
Why It Matters
If MDSAP becomes the sole GMP pathway in Brazil, manufacturers without MDSAP certification will face a hard barrier to market entry. Companies currently relying on direct ANVISA inspection for B-GMP certification should begin MDSAP transition planning now. The SaMD revision will affect every digital health company targeting Brazil.
COFEPRIS published the interpretation criteria for NOM-241-SSA1-2025, recognizing the Medical Device Single Audit Program (MDSAP) as equivalent to Mexico's GMP certification. This means a single MDSAP audit report can now replace the NOM-241 conformity assessment for both domestic and international manufacturing sites — eliminating duplicate regulatory procedures for quality system compliance.
The recognition applies to all sanitary registration applications for medical devices, whether through the abbreviated or standard procedure. Manufacturers with valid MDSAP audit reports can submit them in lieu of separate NOM-241 certification, regardless of where the manufacturing site is located.
Bottom Line
For device companies with MDSAP certification, Mexico just removed a major redundancy from the registration process. Combined with COFEPRIS's 30-day abbreviated device pathway for FDA/IMDRF-approved products, Mexico is now one of the fastest-to-market destinations in LATAM for devices with existing international approvals.
The European Commission confirmed that the EU-Mercosur Interim Trade Agreement (iTA) will provisionally apply as of May 1, 2026, covering trade-related provisions including tariff reductions. Argentina, Brazil, and Uruguay have submitted their notifications; Paraguay has ratified the agreement.
For medical devices, the agreement phases out tariffs that currently reach up to 16% on EU-manufactured products entering Mercosur markets. It also introduces national treatment provisions — meaning EU-originating medical technologies must receive treatment no less favorable than locally manufactured devices in Argentina, Brazil, Uruguay, and Paraguay. The agreement does not replace existing regulatory compliance requirements (ANVISA authorization, ANMAT registration, etc.), but is expected to improve transparency and regulatory cooperation over time.
What to Focus On
EU device manufacturers with CE marking should model the tariff impact on their Mercosur pricing strategies. The national treatment clause is particularly significant for public procurement — historically, several Mercosur countries have applied preferential treatment to locally manufactured devices in government tenders.
Ecuador's ARCSA introduced new certification requirements on March 31, 2026 for establishments involved in the storage, distribution, and transportation of medical devices. The regulations mandate compliance with Good Storage, Distribution, and Transport Practices (BPA/BPD/BPT), including secure temperature-controlled environments.
Businesses must notify ARCSA within 30 days when outsourcing storage, distribution, or transportation services. All subcontractors must meet the same certification standards required of the primary establishment.
Why It Matters
Ecuador is the first of the smaller LATAM markets to formalize post-import supply chain certification for devices. For manufacturers using third-party distributors in Ecuador, the new rules require verifying that your distribution partner holds current BPA/BPD/BPT certification — or risk supply chain interruption
← All LATAM Regulatory Dispatch editions · Contact bioaccess®